Antipsychotic-induced extrapyramidal symptoms and their management

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 9, 2008, Pages 1451-1462

  Dalaya, Praveen ^a   Chou, Kelvin L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Akathisia; Amantadine; Anticholinergic; Antipsychotic; Basal ganglia; Clozapine; Dopamine; Dyskinesia; Dystonia; Extrapyramidal; Haloperidol; Movement disorder; Neuroleptic; Parkinsonism; Prevention; Propranolol; Psychosis; Quetiapine; Receptor; Schizophrenia; Side effects; Tardive; Tetrabenazine; Treatment; Vitamin E

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; CLOZAPINE; FLUNARIZINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; MESORIDAZINE; METOCLOPRAMIDE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; UNINDEXED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGRANULOCYTOSIS; AKATHISIA; BINDING AFFINITY; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG WITHDRAWAL; DYSTONIA; EPIDEMIOLOGICAL DATA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; PARKINSONISM; PATHOPHYSIOLOGY; PHENOMENOLOGY; PSYCHOSIS; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; EXTRAPYRAMIDAL SYNDROME;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; HUMANS;

EID: 46749102129     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.9.1451     Document Type: Review

References (140)

1. Wilson SAK. Progressive lenticular degeneration: a familial nervous system disease associated with cirrhosis of the liver. Brain 1912;34:295-507
2. Fahn S. Concept and classification of dystonia. In: Fahn S, Marsden CD, Calne DB, editors, Dystonia 2. New York: Raven Press; 1988. p. 2-8
3. Kipps CM, Fung VS, Grattan-Smith P, et al. Movement disorder emergencies. Mov Disord 2005;20(3):322-34
4. Braude WM, Barnes TRE, Gore SM. Clinical Characteristics of Akathisia - a Systematic Investigation of Acute Psychiatric Inpatient Admissions. Br Psychiatry 1983;143:139-50
5. Burke RE, Kang UJ, Jankovic J, et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4(2):157-75
6. Sachdev P. Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale and proposal. Psychopharmacology 1994;114(1):181-6
7. Munetz MR, Cornes CL. Distinguishing akathisia and tardive dyskinesia: a review of the literature. J Clin Psychopharmacol 1983;3(6):343-50
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text revision. Washington, DC: American Psychiatric Association; 2000
9. Feve A, Angelard B, Fenelon G, et al. Postneuroleptic laryngeal dyskinesias: a cause of upper airway obstructive syndrome improved by local injections of botulinum toxin. Mov Disord 1993;8(2):217-9
10. Gerratt BR, Goetz CG, Fisher HB. Speech abnormalities in tardive dyskinesia. Arch neurol 1984;41(3):273-6
11. Wilcox PG, Bassett A, Jones B, Fleetham JA. Respiratory dysrhythmias in patients with tardive dyskinesia. Chest 1994;105(1):203-7
12. Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987;50(6):801-3
13. Yassa R, Nair V, Iskandar H. A comparison of severe tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand 1989;80(2):155-9
14. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121(Pt 11):2053-66
15. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32(12):1335-46
16. Kang UJ, Burke RE, Fahn S. Natural-History and treatment of tardive dystonia. Neurology 1986;36(4):121
17. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-60
18. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96
19. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991;324(11):746-54
20. Weissman EM. Antipsychotic prescribing practices in the veterans healthcare administration - New York metropolitan region. Schizophr bull 2002;28(1):31-42
21. Meltzer HY. Mechanism of action of atypical antipsychotic drugs. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors, Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lipppincott, Williams, and Wilkins; 2002. p. 819-33
22. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;65(Suppl 9):25-8
23. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-93
24. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16(1):23-45
25. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1081-90
26. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157(4):514-20
27. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158(3):360-9
28. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40(10):1113-7
29. Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-unduced acute dystonic reactions. J Clin Psychopharmacol 1987;7(3):164-6
30. C S Jr. Drug-induced dystonia. Am J Psychiatry 1975;132(5):532-4
31. Chakos MH, Mayerhoff DI, Loebel AD, et al. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992;28(1):81-6
32. Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 1987;7(5):342-5
33. Aguilar EJ, Keshavan MS, Martínez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994;151(12):1819-21
34. VanHarten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. Br Med J 1999;319(7210):623-6
35. Westerink BH. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol 2002;455(1):1-18
36. J AF Jr. High potency neuroleptics and akathisia. J Clin Psychopharmacol 1984;4(4):237
37. Guttmacher MS. Phenothiazine Treatment In Acute Schizophrenia; Effectiveness: the national institute of mental health psychopharmacology service center collaborative study group. Arch Gen Psychiatry 1964;10:246-61
38. Van Putten T, May PR, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984;41(11):1036-9
39. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
40. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994;51(12):963-74
41. Sachdev P. The epidemiology of drug-induced akathisia: part I. Acute akathisia. Schizophr bull 1995;21(3):431-49
42. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976 - 1990. Neurology 1999;52(6):1214-20
43. Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 2006;21(6):800-8
44. Benito-Leon J, Bermejo-Pareja F, Rodriguez J, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003;18(3):267-74
45. Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 1999;19(4):322-8
46. Caligiuri MP, Lohr JB. Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients. J Neuropsychiatry Clin Neurosci 1997;9(4):562-7
47. Dean CE, Kuskowski MA, Caligiuri MP. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions. J Clin Psychopharmacol 2006;26(6):560-5
48. Marsden CD, Mindham RHS, Mackay AVP. Extapyramidal movement disorders produced by antipsychotic drugs. In: Bradley PB, editor, Psychopharmacology and treatment of schizophrenia. London: Oxford University Press; 1986. p. 340-402
49. L KH Jr, Bergen D, Bruyn GW. Prolonged drug-induced parkinsonism. Conf Neurol 1973;35(6):368-77
50. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2(8411):1082-3
51. Kennedy PF, Hershon HI, McGuire RJ. Extrapyramidal disorders after prolonged phenothiazine therapy. Br J Psychiatry 1971;118(546):509-18
52. Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005;53(8):1374-9
53. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35(1):51-68
54. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ Clin Res Ed 2000;321(7273):1371-6
55. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361(9369):1581-9
56. Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005;165(16):1882-8
57. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14(3):191-210
58. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355(15):1525-38
59. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15(2):201-11
60. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39(4):473-81
61. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980;37(12):1368-73
62. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18(4):701-15
63. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998;155(11):1521-8
64. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord 2006;21(5):589-98
65. Green P. Tardive dystonia. In: Yassa R, Nair NPV, Jeste DV, editors, Neuroleptic-induced movement disorders. Cambridge: Cambridge University Press; 1997. p. 395-408
66. Kahn EM, Munetz MR, Davies MA, Schulz SC. Akathisia: clinical phenomenology and relationship to tardive dyskinesia. Compr Psychiatry 1992;33(4):233-6
67. van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res 1996;19(2-3):195-203
68. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004;161(1):160-3
69. Halliday J, Farrington S, Macdonald S, et al. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002;(181):422-7
70. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22(1):254-8
71. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993;50(9):723-33
72. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414-25
73. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52(9):756-65
74. Dixon L, Weiden PJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992;33(2):121-2
75. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990;16(1-2):57-66
76. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54(9):327-30
77. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990;157:585-92
78. Quitkin F, Rifkin A, Gochfeld L, Klein DF. Tardive dyskinesia: are first signs reversible? Am J Psychiatry 1977;134(1):84-7
79. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994;151(6):836-41
80. Casey DE, Povlsen UJ, Meidahl B, Gerlach J. Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment. Psychopharmacol Bull 1986;22(1):250-3
81. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001;56(6):805-7
82. Sramek JJ, Simpson GM, Morrison RL, Heiser JF. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. J Clin Psychiatry 1986;47(6):305-9
83. Goff DC, Arana GW, Greenblatt DJ, et al. The Effect of Benztropine on Haloperidol-Induced Dystonia, Clinical Efficacy and Pharmacokinetics - a Prospective, Double-Blind Trial. J Clin Psychopharmacol 1991;11(2):106-12
84. Arana GW, Goff DC, Baldessarini RJ, Keepers GA. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988;145(8):993-6
85. Waugh WH, Metts JC Jr. Severe extrapyramidal motor activity induced by prochlorperazine. Its relief by the intravenous injection of diphenhydramine. N Engl J Med 1960;262:353-4
86. Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 1978;135(10):1232-3
87. Korczyn AD, Goldberg GJ. Intravenous diazepam in drug-induced dystonic reactions. Br J Psychiatry 1972;121(560):75-7
88. Adler LA, Peselow E, Rosenthal M, Angrist B. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull 1993;29(2):283-6
89. Baskak B, Atbasoglu EC, Ozguven HD, et al. The effectiveness of intramuscular biperiden in acute akathisia - a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2007;27(3):289-94
90. Lipinski JF, Zubenko GS, Cohen BM, Barreira PJ. Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1984;141(3):412-5
91. Adler L, Angrist B, Peselow E, et al. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986;149:42-5
92. Kramer MS, Gorkin RA, Dijohnson C, Sheves P. Propranolol in the treatment of neuroleptic-induced akathisia (Nia) in schizophrenics - a double-blind, placebo-controlled study. Biol Psychiatry 1988;24(7):823-7
93. Reiter S, Adler L, Angrist B, et al. Atenolol and propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1987;7(4):279-80
94. Wells BG, Cold JA, Marken PA, et al. A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. J Clin Psychiatry 1991;52(6):255-60
95. Zubenko GS, Lipinski JF, Cohen BM, Barreira PJ. Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res 1984;11(2):143-9
96. Poyurovsky M, Shardorodsky M, Fuchs C, et al. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin - Double-blind, placebo-controlled study. Br J Psychiatry 1999;174:238-42
97. Poyurovsky M, Pashinian A, Weizman R, et al. Low-dose mirtazapine: A new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006;59(11):1071-7
98. Fischel T, Hermesh H, Aizenberg D, et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 2001;21(6):612-5
99. Pujalte D, Bottai T, Hue B, et al. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol 1994;17(3):236-42
100. Kutcher S, Williamson P, Mackenzie S, et al. Successful donazepam treatment of neuroleptic-induced akathisia in older adolescents and young-adults - a double-blind, placebo-controlled study. J Clin Psychopharmacol 1989;9(6):403-6
101. Friedman JH, Skeete R, Fernandez HH. Unrecognized parkinsonism in acute care medical patients receiving neurological consultations. J Gerontol A Biol Sci Med Sci 2003;58(1):94-5
102. Miller LG, Jankovic J. Metoclopramide-Induced movement-disorders - clinical findings with a review of the literature. Arch Intern Med 1989;149(11):2486-92
103. Pall HS, Williams AC. Extrapyramidal disturbances caused by inappropriate prescribing. Br Med J 1987;295(6589):30-1
104. Friedman JH, Fernandez HH, Trieschmann MM. Parkinsonism in a nursing home: underrecognition. J Geriatr Psychiatry Neurol 2004;17(1):39-41
105. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment - a consensus statement. Br J Psychiatry 1990;156:412
106. Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly - a case-control study. Am J Med 1995;99(1):48-54
107. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004;161(1):116-24
108. Raedler TJ, Bymaster FP, Tandon R, et al. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007;12(3):232-46
109. Johnstone EC, Crow TJ, Ferrier IN, et al. Adverse-Effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983;13(3):513-27
110. Buhrich N, Weller A, Kevans P. Misuse of anticholinergic drugs by people with serious mental illness. Psychiatric Serv 2000;51(7):928-9
111. Zemishlany Z, Aizenberg D, Weiner Z, Weizman A. Trihexyphenidyl (Artane) abuse in schizophrenic patients. Int Clin Psychopharmacol 1996;11(3):199-202
112. Konig P, Chwatal K, Havelec L, et al. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996;33(2):80-4
113. Wilcox JA, Tsuang J. Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 1990;23(3):144-6
114. Nestelbaum Z, Siris SG, Rifkin A, et al. Exacerbation of schizophrenia associated with amantadine. Am J Psychiatry 1986;143(9):1170-1
115. Hardie RJ, Lees AJ. Neuroleptic-Induced parkinsons syndrome - clinical-features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51(6):850-4
116. Kennedy NJ, Sanborn JS. Disclosure of tardive dyskinesia: effect of written policy on risk disclosure. Psychopharmacol Bull 1992;28(1):93-100
117. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27(1):105-19
118. Liao DL, Yeh YC, Chen HM, et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001;44(2):95-8
119. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007;27(2):159-69
120. Soares Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2007;3
121. Gourzis P, Polychronopoulos P, Papapetropoulos S, et al. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics - a report of 2 cases. Clin Neuropharmacol 2005;28(4):195-6
122. Louza MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia with clozapine - 5 years' follow-up. J Clin Psychopharmacol 2005;25(2):180-2
123. Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004;65(5):696-701
124. Bunker MT, Sommi RW, Stoner SC, Switzer JL. Longitudinal analysis of abnormal involuntary movements in long-term clozapine-treated patients. Psychopharmacol Bull 1996;32(4):699-703
125. Gerlach J, Peacock L. Motor and mental side-effects of dozapine. J Clin Psychiatry 1994;55(9):107-9
126. Jankovic J, Hunter CB, Mejia N, Vuong K. Tetrabenazine: effective treatment for tardive dyskinesia. Mov Disord 2004;19:S73
127. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48(2):358-62
128. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol. Am J Psychiatry 1999;156(8)1279-81
129. Huang CC, Wang RIH, Hasegawa A, Alverno L. Reserpine and alpha-methyldopa in the treatment of tardive-dyskinesia. Psychopharmacology (Berl) 1981;73(4):359-62
130. Zhang XY, Zhou DF, Cao LY, et al. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: A double-blind placebo-controlled trial. J Clin Psychopharmacol 2004;24(1):83-6
131. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996;57(4):167-73
132. Adler LA, Peselow E, Rotrosen J, et al. Vitamin-E treatment of tardive-dyskinesia. Am J Psychiatry 1993;150(9):1405-7
133. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry 1999;56(9):836-41
134. Soares KVS, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2007;3
135. Wojcik JD, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991;148(8):1055-9
136. Kanovsky P, Streitova H, Bares M, Hortova H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect. Mov Disord 1999;14(5):886-8
137. Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998;13(1):158-61
138. Tarsy D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997;20(1):90-3
139. Bhoopathi PS, SoaresWeiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2007;3
140. Soares KVS, Rathbone J, Deeks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2007;3